Effect of exemestane plus everolimus on CTC counts and Ki-67 expression on CTCs in patients with advanced hormone receptor-positive, HER2-negative breast cancer.
Sofia Agelaki
No relevant relationships to disclose
Maria Spiliotaki
No relevant relationships to disclose
Christos Nikolaou
No relevant relationships to disclose
Eleni Politaki
No relevant relationships to disclose
Stella Apostolaki
No relevant relationships to disclose
Athanasios Kotsakis
No relevant relationships to disclose
Dimitrios Mavroudis
No relevant relationships to disclose
Vassilis Georgoulias
Consultant or Advisory Role - Novartis